New Publication

Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized BRGSF-HIS preclinical model

Authors: Gaëlle H. Martin¹, Alexis Gonon¹, Perrine Martin-Jeantet¹, Florence Renart-Depontieu¹, Zuzana Biesova², Anokhi Cifuentes², Arnab Mukherjee², Thomas Thisted², Astrid Doerner³, Dean O. Campbell³, Ludovic Bourre´³, Edward H. van der Horst², Ame´ lie Rezza¹ and Kader Thiam<sup>1

1</sup>genOway, Lyon, France, ²Sensei Biotherapeutics Inc., Boston, MA, United States, ³Crown Bioscience Inc., San Diego, CA, United States

Some immunotherapies have been shown to induce immune-related adverse events, including the potentially life-threatening cytokine release syndrome (CRS).

As a result, there is a need for reliable and translational preclinical models to predict potential safety issues and investigate their rescue.

The study presented in this article tested the reliability of humanized BRGSF mice for the assessment of therapeutics-induced CRS features in preclinical settings. The study included the investigation of human myeloid and dendritic cells’ contribution in hFlt3L-boosted BRGSF-CBC mice.

Read the full article, published in Frontiers in Immunology, for an in-depth review of the study aim, methods, and results.